Altimmune Q3 2025 Earnings Preview
This article provides a brief earnings preview for Altimmune's Q3 2025 results. It mentions that the company is expected to announce its earnings.
Altimmune's Q1 loss narrower than expected, revenues nil
Altimmune announced a narrower-than-expected loss for the first quarter of 2026, with no revenues reported. This suggests the company is still in a developmental or pre-commercialization phase. Investors will be watching for future developments regarding their product pipeline and potential revenue generation.
H.C. Wainwright cuts Altimmune stock price target on dilution
H.C. Wainwright has lowered its price target for Altimmune (NASDAQ:ALT) from $25 to $20, while maintaining a Buy rating on the stock, due to share-count dilution from recent capital raises. Despite this adjustment, the analyst consensus remains bullish, and the company has announced key operational updates including the finalization of its Phase 3 MASH trial and progress in its alcohol use disorder and alcohol-associated liver disease trials, with significant cash reserves to fund operations through 2029. Citizens also adjusted its price target to $11 from $14, keeping a Market Outperform rating.
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright has reiterated its Buy rating for Altimmune (ALT.US) and maintained a target price of $20. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
H.C. Wainwright cuts Altimmune stock price target on dilution
H.C. Wainwright lowered its price target for Altimmune (NASDAQ:ALT) to $20 from $25, while maintaining a Buy rating, citing share-count dilution from recent capital raises. Despite the cut, the analyst consensus remains bullish. Altimmune recently reported Q1 2026 results, finalized its Phase 3 MASH trial submission, and expects topline data from its Phase 2 alcohol use disorder trial in Q3 2026, with sufficient cash to fund operations through 2029.
Several Insiders Invested In Altimmune Flagging Positive News
Several insiders at Altimmune, Inc. have recently purchased shares, signaling positive sentiment towards the company. Over the last 12 months, the Chairman made a significant purchase, and in the last quarter, insiders collectively bought US$198k worth of shares, with no selling reported. While insider ownership is relatively low at 0.5%, the buying activity suggests optimism for Altimmune's future, despite the company having reported a loss last year.
H.C. Wainwright cuts Altimmune stock price target on dilution By Investing.com
H.C. Wainwright has lowered its price target on Altimmune (NASDAQ:ALT) to $20 from $25, while maintaining a Buy rating. The reduction is attributed to share-count dilution from recent capital raises in January and April. Despite the cut, Altimmune reported better-than-expected Q1 2026 earnings and is advancing its Phase 3 MASH trial and Phase 2 alcohol use disorder and alcohol-associated liver disease trials, with significant cash reserves to fund operations through 2029.
Altimmune Price Target Cut to $20.00/Share From $25.00 by HC Wainwright & Co.
HC Wainwright & Co. has lowered its price target for Altimmune (NASDAQ: ALT) shares from $25.00 to $20.00. The firm maintained a "Buy" rating on the stock. This adjustment reflects a revised outlook from the analyst despite the continued positive recommendation.
Tang Capital (ALT) reports 666,022 shares, 0.3% stake in Altimmune (ALT)
Tang Capital Management, LLC and related entities have reported a passive beneficial ownership of 666,022 shares in Altimmune (ALT), representing a 0.3% stake. This information was disclosed in an amended SCHEDULE 13G/A filing with the SEC, based on 194,199,358 shares outstanding as of April 24, 2026. The filing indicates shared voting and dispositive power among Tang Capital Management, Tang Capital Partners International, LP, and Kevin Tang, confirming it falls under the "Ownership of 5 Percent or Less of a Class" category.
Altimmune's Q1 loss narrower than expected, revenues nil
Altimmune reported a narrower-than-expected loss for the first quarter, although the company's revenues were nil. This indicates that despite no incoming revenue, the company managed to control its expenses better than anticipated by analysts.
ALT: Altimmune Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides the latest stock price, analysis, news, and trading ideas for Altimmune Inc (ALT). It highlights key financial figures, recent earnings, and both bullish and bearish sentiments regarding the company's performance and future outlook. Altimmune reported GAAP EPS of -$0.18, secured a strong cash position, and is advancing its pemvidutide trial with FDA Breakthrough Therapy Designation.
Altimmune, Inc. (NASDAQ:ALT) Q1 2026 Earnings Call Transcript
Altimmune, Inc. reported its Q1 2026 financial results, beating earnings expectations with an EPS of $-0.18 against an expectation of $-0.25. The company shared updates on its lead drug, pemvidutide, for MASH, AUD, and ALD, highlighting its differentiated profile, strong tolerability, and the initiation of its global Phase III MASH trial (PERFORMA) in the second half of 2026. Altimmune also announced a successful $225 million public offering, providing a cash runway through the Phase III MASH 52-week data readout expected in 2029.
Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
Altimmune announced its plans to initiate the PERFORMA Phase III trial for MASH in the second half of 2026. The company also stated that its current cash reserves are sufficient to fund operations through the 52-week readout of the trial in 2029. This update provides a timeline for Altimmune's key clinical development and financial stability regarding its MASH program.
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript Summary
This document is a summary of Altimmune, Inc.'s Q1 2026 Earnings Call Transcript. As the full content was not provided, no further details can be extracted.
Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cas
Altimmune Inc (ALT) reported a strong cash position of approximately USD535 million as of April 2026, bolstered by a USD225 million public offering. Despite increased R&D and G&A expenses leading to a net loss of USD22.6 million in Q1 2026, the company's financial runway is secured through the Phase III MASH 52-week data readout in 2029. Pemvidutide, their lead drug candidate, has received Breakthrough Therapy designation, and its Phase II IMPACT trial showed promising efficacy, with Phase III trials aligned with regulatory feedback from the FDA and EMA.
William Blair Maintains Altimmune(ALT.US) With Hold Rating
William Blair has reiterated its "Hold" rating on Altimmune (ALT.US). This indicates that the firm advises investors to maintain their current position in the stock.
Biotech Altimmune banks $535M, plans Phase 3 liver trial
Altimmune announced its first quarter 2026 financial results, reporting a net loss of $22.6 million but significantly strengthening its cash position to $535 million through recent equity financings. The company plans to initiate its global PERFORMA Phase 3 MASH trial in the second half of 2026, building on the FDA's Breakthrough Therapy Designation for Pemvidutide. Additionally, Altimmune anticipates topline data from its RECLAIM Phase 2 AUD trial and completion of enrollment for the RESTORE Phase 2 ALD trial in the third quarter of 2026.
Altimmune reports Q1 net loss $22.6M, cash position $332M as of March 31, 2026
Altimmune reported a net loss of $22.6 million for the first quarter ended March 31, 2026, with a cash position of $332.0 million, which increased to $535 million after an April public offering. The company plans to initiate the PERFORMA Phase 3 MASH trial in H2 2026, building on pemvidutide's Breakthrough Therapy Designation for MASH. Additionally, Altimmune anticipates topline data for its RECLAIM Phase 2 trial in AUD in Q3 2026 and continues enrollment for the RESTORE Phase 2 trial in ALD.
Altimmune (ALT) boosts cash to $535M as it prepares Phase 3 MASH trial
Altimmune (ALT) reported its Q1 2026 financial results, including a net loss of $22.6 million, and announced a significant boost to its cash reserves, reaching $535 million as of April 30, 2026, following recent financing events. The company is preparing to initiate its Phase 3 MASH trial (PERFORMA) in the second half of 2026 and expects topline Phase 2 data for alcohol use disorder (AUD) and enrollment completion for alcohol-associated liver disease (ALD) trials later this year. Pemvidutide, Altimmune's lead drug, holds FDA Fast Track designations for MASH and AUD, and Breakthrough Therapy Designation for MASH, highlighting its potential in addressing serious liver diseases.
Altimmune (ALT) Set to Release Q1 Earnings on May 13th
Altimmune (ALT) is scheduled to release its Q1 earnings on May 13th, with analysts anticipating an EPS of -$0.25 and $0 million in revenue. The company, a clinical-stage biopharmaceutical firm, is focusing on its key drug candidate, pemvidutide, for serious liver diseases. Despite a low GF Score™ of 38, indicating financial challenges, recent insider buying activity suggests some confidence in its future prospects.
State Street (ALT) reports 5.5% ownership — 7.15M shares disclosed
State Street Corporation has disclosed a 5.5% beneficial ownership stake in Altimmune Inc. (ALT), amounting to 7,145,550 shares, as per a Schedule 13G SEC filing. This institutional ownership is characterized by shared voting and dispositive power and signals a passive, index-related investment rather than active takeover intent. The filing was signed by Elizabeth Schaefer on May 12, 2026, based on holdings as of March 31, 2026.
Altimmune Inc expected to post a loss of 24 cents a share - Earnings Preview
Altimmune Inc (ALT) is projected to report a loss of 24 cents per share. This information comes from Refinitiv and is part of an earnings preview. The company's stock symbol is ALT.
Earnings Preview: Altimmune to Report Financial Results Pre-market on May 13
This article serves as an earnings preview for Altimmune (NASDAQ: ALT), detailing that the company is scheduled to release its financial results pre-market on May 13. Investors will be keen to see if the company beats or misses earnings and revenue estimates. The article also provides historical performance data regarding past earnings reports.
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Altimmune, Inc. announced it will report its first-quarter 2026 financial results and provide a business update on Wednesday, May 13, 2026. Management will host a conference call at 8:30 a.m. ET to discuss these results. The call will be webcast live on the company's Investor Relations website.
ALT SEC Filings - Altimmune 10-K, 10-Q, 8-K Forms
This article provides access to Altimmune's (ALT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events. It highlights the importance of these documents for investors to understand the company's clinical, financial, and corporate activities, especially concerning its peptide-based therapeutics for liver, metabolic, and cardiometabolic diseases. Stock Titan offers near real-time updates of these filings, along with AI-powered summaries and impact analysis to help users navigate complex financial information.
Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook
Altimmune Inc. (NASDAQ: ALT) experienced an 8.46% stock increase following positive clinical trial progress, contrasting with a dip after a $225 million offering. Despite minimal revenue and negative margins, the company boasts a strong balance sheet post-financing, with cash and short-term investments of approximately $273 million. Analysts view the financing as crucial for funding the Phase 3 pemvidutide trial, providing a multi-year runway despite high operating cash burn.
Altimmune (ALT) director receives 48,800-share stock option grant
Altimmune, Inc. director Diane Jorkasky received a grant of stock options for 48,800 shares of common stock as compensation. The options have an exercise price of $2.82 per share and expire on May 1, 2036. These options will vest in substantially equal monthly installments over 12 months, contingent on her continued service as a non-employee director.
Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price
Altimmune, Inc. director Philip Hodges has been granted 48,800 stock options with an exercise price of $2.82 per share, expiring on May 1, 2036. This award is part of his non-employee director compensation policy. The options will vest in substantially equal monthly installments over 12 months, starting May 1, 2026, provided Hodges continues his service to the company.
[Form 4] Altimmune, Inc. Insider Trading Activity
Altimmune, Inc. director Wayne Pisano was granted stock options to acquire 48,800 shares of common stock at an exercise price of $2.82 per share. This grant is part of the company's non-employee director compensation policy. The options will vest monthly over 12 months starting May 1, 2026, contingent on Mr. Pisano's continued service, and expire on May 1, 2036.
[Form 4] Altimmune, Inc. Insider Trading Activity
Altimmune, Inc. director John Gill was granted options for 48,800 shares of common stock at an exercise price of $2.82 per share, expiring on May 1, 2036. This grant is part of his non-employee director compensation policy and is a routine, compensation-related award rather than an open-market transaction. The options will vest in substantially equal monthly installments over 12 months following May 1, 2026, contingent on his continued service.
Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares
Deep Track Capital, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and Deep Track Special Opportunities Fund, LP, and David Kroin, has reported a 9.99% beneficial ownership stake in Altimmune (ALT). This stake, amounting to 19,417,221 shares, includes common stock, pre-funded warrants, and warrants, all subject to a 9.99% maximum exercise limitation. The disclosure was made via a Schedule 13G filing as of April 30, 2026 and is based on 194,366,579 shares outstanding.
Altimmune closes $225M financing for MASH drug trial
Altimmune Inc. has successfully completed a $225 million public offering consisting of common stock and pre-funded warrants to fund its upcoming Phase 3 trial for pemvidutide, a treatment for MASH. The financing is expected to provide the company with a cash runway through the anticipated 52-week data readout of the trial. Despite the stock trading near its 52-week low, analysts have revised earnings upwards, and Goldman Sachs upgraded its rating to Neutral following the capital raise.
Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch
Altimmune has secured $225 million to fund a phase 3 study of a GLP-1 therapy for a severe liver disease that impacts up to 12% of U.S. adults. This funding will help the company advance its clinical trials and potentially bring its first commercial product to market. Jerry Durso is the president and CEO of Altimmune, based in Gaithersburg, MD.
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns
Altimmune (ALT) stock fell after reporting a larger-than-expected Q4 loss, primarily due to increased R&D expenses for its obesity drug, pemvidutide. Despite the negative financial news, retail investors remain optimistic about a potential partnership deal for pemvidutide, which they believe could resolve the company's cash flow concerns and boost the stock price.
Altimmune closes $225M financing for MASH drug trial By Investing.com
Altimmune Inc. has successfully completed a public offering, raising approximately $225 million to fund its upcoming Phase 3 trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). This financing, which included shares and pre-funded warrants, provides the company with a cash runway through the anticipated 52-week data readout of the trial. Despite its stock trading near a 52-week low, Altimmune maintains a strong balance sheet and has received positive analyst revisions and a rating upgrade from Goldman Sachs.
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. announced the closing of a $225 million oversubscribed public offering, including common stock and accompanying warrants. This financing, led by Deep Track Capital and other significant investors, will fund the initiation and execution of the pemvidutide Phase 3 trial in MASH, providing a cash runway through the anticipated 52-week data readout. The company aims to develop pemvidutide as a differentiated therapy for serious liver diseases.
Altimmune raises $225M to fund late-stage MASH drug trial
Altimmune (Nasdaq: ALT) successfully closed an oversubscribed public offering, securing approximately $225 million in gross proceeds. This funding is earmarked to finance the planned Phase 3 MASH trial for its drug pemvidutide and extend its cash runway through the anticipated 52-week data readout, with trial initiation expected in the second half of 2026. The offering involved common shares and accompanying common stock warrants, with pre-funded warrants also made available to certain investors.
Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock
Altimmune Inc. (ALT) is highlighted as an attractive penny stock due to positive analyst coverage and its promising drug candidate, pemvidutide. Truist initiated coverage with a "Buy" rating and a $12 price target, citing pemvidutide's potential in treating MASH and liver-related disorders with estimated peak revenues of $600 million-$1 billion. H.C. Wainwright also reaffirmed its "Buy" rating, increasing its price target to $25, based on the company's MASH pivotal program and efforts against alcohol-related illnesses.
LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff?
This article notes that Lululemon Athletica Inc. (LULU), Lucid Group, Inc. (LCID), and Altimmune, Inc. (ALT) stocks all reached new 52-week lows. The article title suggests it will explore the reasons behind these selloffs, but the content provided is incomplete. An analysis would typically delve into recent company news, earnings reports, analyst ratings, and broader market trends affecting these companies.
Altimmune Raises ~$211 Million in Stock-and-Warrant Offering Led by Leerink and Barclays
Altimmune (ALT) has successfully raised approximately $211.2 million in net proceeds through a stock-and-warrant offering. The offering included 64.25 million shares of common stock and up to 10.75 million pre-funded warrants, priced at $3.00 per share and $2.999 per pre-funded warrant, respectively. The company intends to use these funds for the Phase 3 development of pemvidutide in MASH, pre-commercial activities, and general corporate purposes.
Altimmune (NASDAQ: ALT) prices $3.00 stock and warrant offering
Altimmune (NASDAQ: ALT) has completed an underwritten public offering of 64,250,000 shares of common stock at $3.00 per share, along with accompanying common stock warrants. The company also issued pre-funded warrants for up to 10,750,000 shares at $2.999 per warrant, expecting net proceeds of approximately $211.2 million. These funds will be used to advance clinical development of pemvidutide, including preparing for a global pivotal Phase 3 trial in MASH, initiating pre-commercial activities, and for general corporate purposes.
Altimmune (NASDAQ: ALT) prices 64.25M shares with warrants to fund Phase 3
Altimmune (NASDAQ: ALT) has priced an underwritten offering of 64.25 million shares of common stock, along with accompanying common stock warrants and pre-funded warrants, aiming to raise approximately $211.2 million in net proceeds. The funds are primarily intended to finance a planned global Phase 3 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis), as well as for working capital and general corporate purposes. The offering includes common stock warrants exercisable for up to 75 million shares at $3.00, expiring five years after issuance or 45 days after a successful Phase 3 pemvidutide readout, and pre-funded warrants with a nominal exercise price that do not expire.
Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position
Altimmune (NASDAQ: ALT) stock experienced a significant drop after reporting mixed results from its Phase 2 trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). While the drug showed positive effects on MASH resolution, the higher dosage arm missed a key secondary endpoint related to fibrosis improvement, leading to investor disappointment and a bearish outlook from a retail analyst.
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
Altimmune's stock (ALT) is largely focused on the drug pemvidutide, which is being developed for three liver-related conditions: MASH, AUD, and ALD. The drug's balanced dual agonist mechanism, targeting both glucagon and GLP-1 receptors, aims to address liver biology and promote weight loss. While its success in late-stage MASH trials is critical for the company's valuation, Altimmune also faces intense competition across all three indications.
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
Altimmune is focusing its investment strategy on pemvidutide, a dual receptor agonist for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD), making 2026 a crucial year. Key catalysts include a late-stage MASH study initiation and Phase II AUD data readout, while continuous financing efforts are critical for its extensive development programs. The company faces stiff competition across all indications and emphasizes pemvidutide's differentiation through liver efficacy, tolerability, and simple dosing.
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’
Altimmune Inc. (ALT) shares dropped significantly in pre-market trading after the biotech company announced a $225 million public offering at a discounted price of $3 per share. This is the second offering this year, leading to dilution fears among investors and negative reactions from retail traders on Stocktwits. The proceeds from the offering are intended to fund the Phase 3 trial of Pemvidutide, a treatment for MASH, which has received FDA Breakthrough Therapy Designation.
$225M Altimmune raise is slated to fund a Phase 3 MASH trial
Altimmune (NASDAQ: ALT) has priced an oversubscribed public offering seeking to raise approximately $225 million in gross proceeds. The funding, which includes common shares and warrants, is primarily intended to finance the company's upcoming Phase 3 clinical trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), as well as for general working capital and corporate purposes. This offering continues Altimmune's strategy of tapping equity markets to support its late-stage MASH development program.
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. announced the pricing of an oversubscribed public offering aimed at raising approximately $225 million. The offering includes common stock and accompanying common stock warrants, or pre-funded warrants, with an exercise price of $3.00 per share for the common stock and $2.999 for pre-funded warrants. The company intends to use the net proceeds to fund its upcoming Phase 3 trial for pemvidutide in MASH, as well as for general corporate purposes.
Altimmune prices $225 million public offering at $3 per share
Altimmune Inc. has priced a public offering of common stock and warrants, expecting to generate $225 million in gross proceeds. The capital raise is intended to fund its upcoming Phase 3 trial for pemvidutide in MASH and for general corporate purposes. This move comes as the company maintains a strong liquidity position despite burning through cash, and has received positive analyst ratings and price targets for its lead asset.
Altimmune Announces Proposed Underwritten Public Offering of Securities
Altimmune, Inc. announced a proposed underwritten public offering of its common stock and accompanying common stock warrants. The biopharmaceutical company intends to use the net proceeds from this offering to fund its upcoming Phase 3 trial for metabolic dysfunction-associated steatohepatitis (MASH), as well as for general corporate purposes. Leerink Partners and Barclays are serving as joint bookrunning managers for the offering.
